- Home
- CTO vs MLYS Comparison
CTO vs MLYS Comparison
Compare CTO & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | MLYS |
|---|---|---|
| Founded | 1902 | 2019 |
| Country | United States | United States |
| Employees | 42 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.7M | 2.4B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | CTO | MLYS |
|---|---|---|
| Price | $18.30 | $23.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $21.50 | ★ $48.67 |
| AVG Volume (30 Days) | 251.9K | ★ 1.1M |
| Earning Date | 04-30-2026 | 03-12-2026 |
| Dividend Yield | ★ 8.10% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $2.76 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.07 | $10.44 |
| 52 Week High | $20.25 | $47.65 |
Technical Indicators
Market Signals| Indicator | CTO | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 30.24 |
| Support Level | $17.72 | $13.42 |
| Resistance Level | $18.55 | $31.09 |
| Average True Range (ATR) | 0.38 | 1.76 |
| MACD | -0.16 | -0.30 |
| Stochastic Oscillator | 1.88 | 11.34 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties in diversified markets in the United States. The company operates in four primary business segments: Income properties, management services, commercial loans and investments, and real estate operations. It derives maximum revenue from Income Properties.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.